Your digital belongings are yours. Who do you want to be in control of them?
It's hard to trust that the companies promising to store our digital assets won't access them and use them for their own benefit. After all, Facebook has grown to a net worth of $100 billion, and Google, $300 billion, from manipulating their product��ustomers' personal information��o deliver lucrative advertising platforms, according to Mother Jones.
Brian Taptich is CEO of Bitcasa(Photo: Bitcasa)
Hot Retail Companies To Own In Right Now: Liquidmetal Technologies Inc (LQMT)
Liquidmetal Technologies, Inc. (Liquidmetal Technologies), incorporated in 1987, is materials technology company that develops and commercializes products made from amorphous alloys. The Company's Liquidmetal family of alloys consists of a variety of bulk alloys and composites that utilize the advantages offered by amorphous alloy technology. The Company designs develop and sell products and components from bulk amorphous alloys to customers in various industries. The Company also partners with third-party manufacturers and licensees to develop and commercialize Liquidmetal alloy products. The Company focused to commercializes its Liquidmetal alloys on three identified product areas, such as Components for Non-Consumer Electronic Products, Sporting Goods and Leisure Products and Medical Devices. On December 1, 2011, the Company entered into a Share Purchase Agreement with LMTK Holdings, Inc. (LMTK Holdings) to sell its former Korean subsidiary and manufacturing facility, Liquidmetal Technologies Korea (LMTK). Under the Share Purchase Agreement, the Company sold all of LMTK�� shares of common stock to LMTK Holdings.
The Company designs, develops and produces components for non-consumer electronic devices utilizing its bulk Liquidmetal alloys. The product categories in the non-consumer electronics field include, but are not limited to, parts for high end printers, commercial imaging devices, aerospace components, medical devices and industrial machines. The Company is also developing a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area.
The Company develops a variety of applications for Liquidmetal alloys in the sporting goods and leisure products area. In the sporting goods industry the Company focuses on products that meet its design criteria. The Company has produced prototype rings made from an amorphous Liquidmetal platinum alloy that is harder, in the leisure products category. The Company emphasis on surgical instrument appl! ications for Liquidmetal alloys. These include, but are not limited to, specialized blades, orthopedic instruments utilized for implant surgery procedures, dental devices and general surgery devices
The Company is engaged in product development efforts relating to various medical devices that could be made from bulk Liquidmetal alloys. The properties of bulk Liquidmetal alloys provide a combination of performance that makes them a replacement to incumbent materials, such as stainless steel and titanium.
Advisors' Opinion:- [By Bryan Murphy]
With just a quick glance at its chart, Liquidmetal Technologies Inc. (OTCBB:LQMT) looks like little more than a tangled, indecisive mess. As you take a longer look at LQMT chart though, a modest bullish hint starts to appear. This may be one of the budding superstar stocks for Q4.
Top 10 Promising Companies To Buy Right Now: iShares 20+ Year Treasury Bond ETF (TLT)
iShares Lehman 20+ Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the long-term sector of the United States Treasury market as defined by the Lehman Brothers 20+ Year U.S. Treasury Index (the Index). The Index includes all publicly issued, the United States Treasury securities that have a remaining maturity greater than 20 years, are non-convertible, are denominated in United States dollars, are rated investment grade (Baa3 or better) by Moody�� Investors Service, are fixed rate, and have more than $150 million par outstanding. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes, state and local government series bonds, and coupon issues that have been stripped from assets that are already included in the Index.
The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.
Advisors' Opinion:- [By Jon C. Ogg]
It is no secret now that interest rates have risen. Long-term Treasury yields and even intermediate Treasury yields are now perhaps even starting to normalize even with Ben Bernanke and the Federal Reserve keeping Fed Funds down at the 0.00% to 0.25% target rate. The problem that is going to startle longer-term bond investors is that the 10-year Treasury Note is getting closer and closer to 3% and the 30-year Treasury Bond is getting closer to 4%. We are seeing that the iShares Barclays 20+ Year Treasury Bond (NYSEMKT: TLT) and the ProShares�UltraShort�20+ Year Treasury (NYSEMKT: TBT) are also starting to reach critical levels.
- [By Chris Ciovacco]
Similarities To 2007-2008?
One way to evaluate any situation in the markets is to compare the present day to previous bearish market turns and look for similarities. The Junk Bond Spyder ETF (JNK) can be used as an excellent proxy for the high-yield debt markets. Since JNK did not start trading until 2008, to go back to the stock market's October 2007 peak, the graph below uses a mutual fund (FIHBX) as a proxy for JNK. The top of the chart shows the S&P 500 for comparison purposes. The ratio of junk debt to conservative debt is below the S&P 500. When the bond ratio rises, demand for junk bonds is greater than demand for conservative Treasuries. Were the debt markets a step ahead of stocks in 2007? Yes, as you can see below, bond investors started to migrate away from junk bonds toward more conservative Treasuries (TLT) well before stocks peaked (falling ratio). The credit markets correctly forecasted the coming risks in June 2007, or four months before a major bear market began in October.
Top 10 Promising Companies To Buy Right Now: Calpine Corp (CPN)
Calpine Corporation (Calpine) is an independent wholesale power producer in the United States. The Company owns and operates primarily natural gas-fired and geothermal power plants in North America and has presence in wholesale power markets in California, Texas and the Mid-Atlantic region of the United States. The Company has invested in clean power generation. It is developing, constructing, owning and operating an environmentally responsible portfolio of power plants. Its portfolio is primarily consists of two types of power generation technologies: natural gas-fired combustion turbines, which are combined-cycle plants, and renewable geothermal conventional steam turbines. The Company is a owner and operator of industrial gas turbines, as well as cogeneration power plants. The Company sells wholesale power, steam, capacity, renewable energy credits and ancillary services to its customers, including utilities, independent electric system operators, industrial and agricultural companies, retail power providers, municipalities and power marketers. It purchases natural gas and fuel oil as fuel for its power plants and engage in related natural gas transportation and storage transactions. The Company also purchases electric transmission rights to deliver power to its customers. In February 2014, the Company announced that it has completed the acquisition of a natural gas-fired, combined-cycle power plant located in Guadalupe County, 30 miles northeast of San Antonio, Texas.
As of December 31, 2011, the Company owned 93 power plants, including two under construction, with an aggregate generation capacity of approximately 28,155 megawatts and 584 megawatts under construction. Its generation capacity includes 77 natural gas-fired power plants, 15 geothermal plants and one photovoltaic solar plant. The Company is a consumer of natural gas in North America. The Company sells a substantial portion of its power and other products under power purchase agreements (PPAs) with a duration greater than ! one year.. The contracted sale of power, steam and capacity from its cogeneration power plants, combustion turbine power plants and geothermal power plants, as well as the sale of renewable energy credits (RECs), from its geothermal and solar power plants, provide a stable source of revenue. The Company produces power for sale to utilities, municipalities, retail power providers, independent electric system operators, large end-use industrial or agricultural customers or power marketers. Its cogeneration power plants produce steam for sale to customers for use in industrial or heating, ventilation and air conditioning operations. The Company provides capacity for sale to retail power providers. It provides ancillary service products to wholesale power markets. It sells RECs from its Geysers Assets in northern California, as well as from its small solar power plant in New Jersey.
The Company�� natural gas-fired power plants primarily utilize two types of design: 3,515 megawatts of simple-cycle combustion turbines and 23,043 megawatts of combined-cycle combustion turbines and a small portion from natural gas-fired steam turbines. Its Geysers Assets are a 725 megawatts fleet of 15 operating power plants in northern California. It leases the geothermal steam fields from which it extracts steam for its Geysers Assets. The Company has leasehold mineral interests in 110 leases comprising approximately 29,019 acres of federal, state and private geothermal resource lands in The Geysers region of northern California. Its leases cover one contiguous area of property that comprises approximately 45 square miles in the northwest corner of Sonoma County and southeast corner of Lake County. Across the fleet, it also has a variety of technologies, including approximately 868 megawatts of capacity from its power plants acquired in the Conectiv Acquisition which have conventional steam turbine technology. The Company also has approximately four megawatts of capacity from solar power generation technology a! t its Vine! land Solar Energy Center in New Jersey.
The Company has 24 natural gas-fired power plants, including two under construction, with the capacity to generate a total of 6,194 megawatts in the Western Electricity Coordinating Council (WECC) North American Electric Reliability Council (NERC) region, which extends from the Rocky Mountains westward. In addition, it owns and operate 15 geothermal power plants located in northern California capable of producing a total of 725 megawatts. The majority of these power plants are located in California, in the California Independent System Operator (CAISO) region; the Company also owns a power plant in Arizona and one in Oregon. The Company has 12 natural gas-fired power plants in the TRE NERC region with the capacity to generate a total of 7,239 megawatts, all of which are physically located in the ERCOT market. It has a total of 31 power plants with 7,914 megawatts of peaking capacity located in the RFC, Northeast Power Coordinating Council (NPCC) and Midwest Reliability Organization (MRO) NERC regions. The Company has 19 operating power plants with the capacity to generate a total of 4,491 megawatts in Eastern PJM. In addition, it has one operating power plant, with the capacity to generate 503 megawatts, located in Western PJM. The company has a total of eight natural gas-fired power plants with the capacity to generate a total of 1,439 megawatts in the NPCC NERC region. Five of these power plants are located in New York.
The Company has 50% ownership interests in two Canadian power plants, with the total capacity to generate 1,088 MW (544 megawatts net attributable to Calpine), located in the NPCC NERC region in Ontario, Canada. The Whitby cogeneration facility is a 50 megawatts facility located in Whitby, Ontario and the Greenfield Energy Centre is a 1,038 megawatts facility located in Courtright, Ontario. The Company has three natural gas-fired power plants with the capacity to generate a total of 1,481 megawatts operating within the M! RO NERC r! egion. The Company has one operating natural gas-fired power plant with the capacity to generate 1,134 megawatts located in the Southwest Power Pool (SPP) NERC region. SPP is an RTO approved by FERC that provides independent administration of the electric power grid. SPP manages an energy-only location based real-time wholesale energy market. The Company has 10 natural gas-fired power plants with the capacity to generate a total of 4,949 megawatts operating within the Southeastern Electric Reliability Council (SERC) and the Florida Reliability Coordinating Council (FRCC) NERC regions.
Advisors' Opinion:- [By Sean Williams]
The first risk NextEra faces is its extraordinarily high levels of debt. It's true that cash flow from electricity generation is steady, but so is the interest it pays on the $28.2 billion in debt the company carries on its balance sheet. Electric utilities don't have much choice when it comes to upgrading or expanding their operations in order to reduce their long-term operating costs other than to take on debt to fund projects. The danger is that sometimes this debt can even put previous darlings out of business. U.S. electric utility Calpine (NYSE: CPN ) , for example, was forced to declare bankruptcy in 2005, weighed down by $17 billion in debt at the time. Calpine's collapse had a lot to do with the weakness in the energy market generated by Enron's collapse a few years prior, but it has also failed to regain its luster since reemerging from bankruptcy.�
Top 10 Promising Companies To Buy Right Now: International Business Machines Corporation(IBM)
International Business Machines Corporation (IBM) provides information technology (IT) products and services worldwide. Its Global Technology Services segment provides IT infrastructure and business process services, including strategic outsourcing, process, integrated technology, and maintenance services, as well as technology-based support services. The company?s Global Business Services segment offers consulting and systems integration, and application management services. Its Software segment offers middleware and operating systems software, such as WebSphere software to integrate and manage business processes; information management software for database and enterprise content management, information integration, data warehousing, business analytics and intelligence, performance management, and predictive analytics; Tivoli software for identity management, data security, storage management, and datacenter automation; Lotus software for collaboration, messaging, and so cial networking; rational software to support software development for IT and embedded systems; business intelligence software, which provides querying and forecasting tools; SPSS predictive analytics software to predict outcomes and act on that insight; and operating systems software. Its Systems and Technology segment provides computing and storage solutions, including servers, disk and tape storage systems and software, point-of-sale retail systems, and microelectronics. The company?s Global Financing segment provides lease and loan financing to end users and internal clients; commercial financing to dealers and remarketers of IT products; and remanufacturing and remarketing services. It serves financial services, public, industrial, distribution, communications, and general business sectors. The company was formerly known as Computing-Tabulating-Recording Co. and changed its name to International Business Machines Corporation in 1924. IBM was founded in 1910 and is based in Armonk, New York.
Advisors' Opinion:- [By Sue Chang]
IBM (IBM) , also on the Dow, is expected to post fourth-quarter earnings of $5.99 a share. ��e maintain our neutral on IBM ahead of their upcoming earnings results. The risk/reward is more balanced at present stock price levels, but ultimately IBM will need to return to growth to drive stock price appreciation,��Joseph Foresi, an analyst at Janney Capital Markets, said in a note.
- [By Jon C. Ogg]
What happens if two industry giants come together to say that the only way they can survive is to merge? It is a serious issue happening around PC sales, and competitors like Gateway/Acer, Lenovo, Asus and others are adding incresing competition as this becomes a commoditized cycle. HP critics might have to actually say that the Carly Fiorina�acquisition of Compaq was not as bad as they always maintained. And you also cannot forget that International Business Machines Corp. (NYSE: IBM) was so tired of competing in PCs that it actually jettisoned its PC business to Lenovo in China.
- [By Matt Thalman]
IBM (NYSE: IBM ) fell hard again. The stock dropped 1.14% during today's trading session, after falling more than 8% last Friday, post its earnings announcement. IBM reported first-quarter results that missed on both the top and bottom lines. Investors seem to be questioning whether the once-dominant company is losing its way or advanced technologies are eating the old-timer's lunch. Many analysts are now pointing toward cloud computing as one cause for IBM's decline in revenue and profit this past quarter, and this development has others changing their long-term perceptive of the company. �
- [By Keith Speights]
IBM (NYSE: IBM ) hopes to change the way physicians provide care with its Watson technology. Big Blue is targeting the natural language capabilities, hypothesis generation, and evidence-based learning capabilities of Watson to support doctors in diagnosing and treating patients. What could be interesting is how this technology might also enable other health-care providers such as nurse practitioners and physician assistants to provide higher level of care.
Top 10 Promising Companies To Buy Right Now: POSCO(PKX)
POSCO engages in the manufacture and sale of steel products in South Korea and internationally. The company offers hot rolled steel for general structures, gas cylinders, hull structures, automobile structural uses, and machine structures; atmospheric corrosion resistant steel; steel for casting and tubing of oilwell pipes; steel for line pipes; and general machine structural steel, alloy steel, and steel for tools and machine parts, as well as steel for ships. It also provides cold rolled, galvanized, electrical, and stainless steel products, as well as titanium products. In addition, it involves in various activities, including engineering and construction, steel work maintenance and machinery installation, computer hardware and software distribution, economic research and consulting, rare and special metals manufacturing, rental houses construction and management, energy and resource development, architecture and consulting, electronic commerce, refractories manufacturi ng and sales, transporting and warehousing, and electricity generation. Further, the company engages in components manufacturing and sales, ferromanganese manufacturing, financial investment, LED lightning, coal trading, mine development, finance, iron ore mining and trading, harbor loading and unloading, spinning and weaving, and paper and cement manufacturing businesses; operates athletic facilities and a distribution center; and invests in venture companies and biotech ventures. POSCO was founded in 1968 and is based in Seoul, South Korea.
Advisors' Opinion:- [By Jake Maxwell Watts]
Markets in Korea were higher for the seventh straight session, after a break for Christmas. The Kospi (KR:SEU) �was up 0.1%, near its highest levels in over three weeks. Index heavyweights Samsung Electronics Co. (KR:005930) � (SSNLF) �lost 0.1%, while steel producer Posco (KR:005490) � (PKX) �and auto manufacturer Kia Motors Co. (KR:000270) � (KIMTF) �gained 1.1% and lost 0.2%, respectively.
- [By Jeff Reeves]
Other options include Korean steel giant Posco (PKX), though admittedly this is much more of a global player and subject to commodity trends instead of South Korean growth.
Top 10 Promising Companies To Buy Right Now: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By Alexander Maxwell]
The market for the treatment of chronic diabetic foot ulcers has been growing and larger companies have been taking notice. Many large pharmaceutical companies have their own treatments for chronic diabetic foot ulcers. The space has also caused some major acquisitions. In 2011, Shire� (NASDAQ: SHPG ) acquired�a drug called Dermagraft for the treatment of slow-healing diabetic foot ulcers, through its $750 million acquisition of�Advanced BioHealing. Dermagraft has been a rather lucrative product for Shire, with $153.8 million in sales�last year. As the market continues to grow, I would look for more partnerships with large pharmaceutical companies, and of course more research and development dollars being devoted toward the chronic diabetic foot ulcers indication.
- [By John Udovich] Viropharma Inc. An international biopharmaceutical company, Viropharma has a pipeline focused on providing patients and physicians with new therapeutic alternatives for unmet medical needs where there are few treatment options available. In mid-September, Viropharma was soaring thanks to buyout rumors. Specifically, unnamed sources�have said that Viropharma was working with the Goldman Sachs Group Inc after attracting interest from suitors that include European drugmakers Sanofi SA (NYSE: SNY), which has been expanding into treatments of rare diseases since its 2010 acquisition of Genzyme Inc,�and Shire PLC (NASDAQ: SHPG), which develops treatments for rare illnesses such as Fabry disease. However, it should be noted that Deutsche Bank sees ViroPharma's base case valuation�at $38 per share, but the company's full value could be as high as $52 per share if the potential buyer has a Hereditary Angioedema sales force already in place. Bloomberg has since reported that the�JMP Group Inc. now says Viropharma could fetch as much as $60 a share while Akiva Felt of Oppenheimer has estimated the�company could fetch as much as $50 a share in a competitive bidding situation. On Monday, small cap Viropharma rose 0.26% to $39.26 (VPHM has a 52 week trading range of $22.12 to $40.89 a share) for a market cap of $2.57 billion plus the stock is up 76.5% since the start of the year, up 30% over the past year and up 186.1% over the past five years.
Top 10 Promising Companies To Buy Right Now: LKA Gold Inc (LKAI)
LKA Gold Inc, formerly LKA International, Inc., incorporated on March 16, 1988, owns certain property interests, including mining claims, water rights, buildings, fixtures, improvements, equipment, and permits situated near Lake City, Colorado. The Company�� the Lake City, Colorado Properties include the Ute-Ule silver mine and milling facility and the Golden Wonder gold mine (respectively, the Ute-Ule Property and the Golden Wonder Property or, collectively, the Properties). The Company owns a 100% interest in the Ute-Ule and Golden Wonder Properties. The Properties consist of certain mining claims and a milling facility located in Hinsdale County, Colorado. As of December 31, 2011, LKA was engaged in exploration and limited production at the Golden Wonder mine.
The Ute-Ule Property consists of 23 patented mining claims located approximately four miles west of Lake City, Colorado. A 100 ton-per-day flotation mill, including various equipment and support facilities, exists on the Ute-Ule Property. The Golden Wonder, near Lake City, Colorado, is located in the historic Colorado Mineral Belt.The Golden Wonder Property consists of three patented and 25 unpatented mining claims located approximately 2- 1/2 miles south of Lake City, Colorado.
Advisors' Opinion:- [By Peter Graham]
Small cap mining stocks US Tungsten Corp (OTCMKTS: USTU) and LKA Gold Inc (OTCMKTS: LKAI) along with biotech Entest BioMedical Inc (OTCMKTS: ENTB) have been getting some attention lately in various investment newsletters with at least one of these stocks being the subject of paid promotions while another could soon be the subject of an investor relations campaign. But will any of these small cap stocks be winners for investors or traders? Here is a quick reality check:
No comments:
Post a Comment